Tainá M. Marques

Most-cited papers

1. Serum NFL discriminates Parkinson disease from atypical parkinsonisms

   Tainá M. Marques, A. van Rumund, P. Oeckl, H. B. Kuiperij +4 more

   2019Neurology136 citations Open access

   Semantic Scholar

   Save

2. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

   Tainá M. Marques, H. B. Kuiperij, Ilona B. Bruinsma, A. van Rumund +4 more

   2016Molecular Neurobiology129 citations Open access

   Semantic Scholar

   Save

3. Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion

   P. Oeckl, S. Anderl-Straub, C. V. von Arnim, I. Baldeiras +13 more

   2022Journal of Neurology Neurosurgery & Psychiatry92 citations

   Semantic Scholar

   Save

4. Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease

   A. van Rumund, Tainá M. Marques, R. Esselink, B. Bloem +1 more

   2020Neurology45 citations Open access

   Semantic Scholar

   Save

5. Decreased cerebrospinal fluid Aβ 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy

   A. D. de Kort, H. B. Kuiperij, Tainá M. Marques, Lieke Jäkel +18 more

   2023Annals of Neurology37 citations Open access

   Semantic Scholar

   Save

6. Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach

   Tainá M. Marques, A. van Rumund, Iris Kersten, Ilona B. Bruinsma +7 more

   2021npj Parkinson's Disease22 citations Open access

   Semantic Scholar

   Save

7. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls

   Tainá M. Marques, A. van Rumund, Ilona B. Bruinsma, Hans Wessels +5 more

   2018Molecular Neurobiology13 citations Open access

   Semantic Scholar

   Save

8. Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders.

   Tainá M. Marques, A. van Rumund, H. B. Kuiperij, M. Verbeek

   2017Handbook of Clinical Neurology6 citations

   Semantic Scholar

   Save

9. Disease Progression, Resilience, and Inflammation Markers During the Coronavirus Disease 2019 Pandemic in Parkinson's Disease

   C. Pauly, E. Glaab, Maxime Hansen, C. Martin-Gallausiaux +5 more

   2022Movement Disorders4 citations Open access

   Semantic Scholar

   Save

10. Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy

    Mark Vervuurt, Xiaoyue Zhu, Joseph M. Schrader, Anna M. Kort +13 more

    2021Neuropathology and Applied Neurobiology2 citations Open access

    Semantic Scholar

    Save

11. Amyloid‐βeta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls

    M. Verbeek, A. D. de Kort, M. Wermer, Tainá M. Marques +9 more

    2021Alzheimer's & Dementia2 citations

    Semantic Scholar

    Save

12. A plasma protein signature for cerebral amyloid angiopathy

    Alpana Singh, Marisa N. Denkinger, A. Leuzy, Kari Dieckhoff +21 more

    2026Acta Neuropathologica1 citations Open access

    Semantic Scholar

    Save

13. Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy

    Mark Vervuurt, Xiaoyue Zhu, Joseph M. Schrader, A. D. de Kort +7 more

    2021Alzheimer's & Dementia1 citations

    Semantic Scholar

    Save

14. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

    Tainá M. Marques, H. B. Kuiperij, Ilona B. Bruinsma, A. van Rumund +4 more

    2016Molecular Neurobiology1 citations Open access

    Semantic Scholar

    Save

15. Prognostic value of plasma brain-derived pTau

    Valentina Ghisays, Marisa N. Denkinger, Alpana Singh, Tainá M. Marques +13 more

    2026medRxiv0 citations Open access

    Semantic Scholar

    Save

16. Comparison of brain-derived versus conventional pTau biomarkers in CSF and plasma for detecting Alzheimer’s disease

    Lydia Trudel, J. Therriault, Valentina Ghisays, Arthur C. Macedo +15 more

    2026Brain Communications0 citations Open access

    Semantic Scholar

    Save

17. Brain‐derived plasma p‐tau217 shows enhanced dynamic range for Alzheimer's disease neuropathological change

    Marisa N. Denkinger, W. Brum, A. Leuzy, Alpana Singh +12 more

    2026Alzheimer's & Dementia0 citations Open access

    Semantic Scholar

    Save

18. Performance of upper-arm capillary blood collection for Alzheimer’s disease and central nervous system biomarkers: comparison of Tasso+ and venous plasma

    Ta Atri, Marisa N. Denkinger, James Liu, Alpana Singh +10 more

    2026medRxiv0 citations Open access

    Semantic Scholar

    Save

19. Developing Topics.

    Marisa N. Denkinger, Sterling C. Johnson, Alpana Singh, James Liu +23 more

    2025Alzheimer's & Dementia0 citations Open access

    Semantic Scholar

    Save

20. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy

    E. van den Berg, A. D. de Kort, Iris Kersten, G. Brinkmalm +22 more

    2023Alzheimer's & Dementia0 citations Open access

    Semantic Scholar

    Save

21. Correction: Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.

    A. D. de Kort, H. B. Kuiperij, Tainá M. Marques, Lieke Jäkel +18 more

    2023Annals of Neurology0 citations Open access

    Semantic Scholar

    Save

22. A disbalance of matrix metalloproteinases and their inhibitors in the cerebrospinal fluid from patients with cerebral amyloid angiopathy

    H. B. Kuiperij, Mark Vervuurt, A. D. de Kort, Iris Kersten +4 more

    2021Alzheimer's & Dementia0 citations

    Semantic Scholar

    Save